Context Therapeutics
CNTX
16 hedge funds and large institutions have $6.3M invested in Context Therapeutics in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 7 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
4.05% less ownership
Funds ownership: 22.24% → 18.19% (-4.1%)
16% less funds holding
Funds holding: 19 → 16 (-3)
33% less capital invested
Capital invested by funds: $9.44M → $6.3M (-$3.14M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$1.64M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$300K |
| 3 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$293K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$105K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$45.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$2.03M |
| 2 |
ACM
Altium Capital Management
New York
|
-$1.31M |
| 3 |
EAM
Empery Asset Management
New York
|
-$954K |
| 4 |
VF
Virtu Financial
New York
|
-$142K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$138K |
CNTX Hedge Fund Activity: Q1 2022 in Review
16 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q1 2022, worth a combined $6.3M — down 33% from $9.44M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CNTX and 4 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Affinity Asset Advisors, opening a new position worth an estimated $1.64M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $2.03M sold.
- 16 institutional investors held Context Therapeutics (CNTX) as of Q1 2022, down from 19 in Q4 2021.
- Funds reported $6.3M of Context Therapeutics stock for Q1 2022, down 33% quarter-over-quarter.
- 4 funds opened new Context Therapeutics positions in Q1 2022 and 7 closed out, a net change of -3 holders.
- The largest Context Therapeutics buyer in Q1 2022 was Affinity Asset Advisors, an estimated $1.64M added.
- The largest Context Therapeutics seller in Q1 2022 was AIGH Capital Management, an estimated $2.03M sold.
Based on aggregated 13F filings for Q1 2022.